Pharming announces enrolment of first patient in multicentre Phase IIb clinical trial of RUCONEST® for the prevention of acute kidney injury after myocardial infarction
Pharming Group announces the filing of its 2020 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission
RUCONEST® (conestat alfa)
RUCONEST® (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of angioedema attacks in patients with HAE
View our financial calendar and what conferences, meetings and congresses we will visit in 2021 on our upcoming events page.
Our innovative technology and processes are aimed at purification and formulation of recombinant products. We are continuously looking for highly talented and motivated individuals to join our team.